A phase I dose-escalation study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in advanced melanoma and other solid tumors.
JOURNAL OF CLINICAL ONCOLOGY（2022）
关键词
advanced melanoma,monoclonal antibody,other solid tumors,dose-escalation,anti-ctla
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要